Is Intuitive Surgical a Buy After Its Latest Earnings Report?

The market is not questioning the franchise; it is questioning the slope. For a business with a large recurring-consumables mix, a modest deceleration in U.S. procedure growth mainly matters through sentiment and multiple compression first, and only later through earnings revisions. In the next 1-3 months, the key debate is whether this was a post-print derating event or the start of a true demand inflection.

Second-order, the slowdown in the core robot’s U.S. growth rate is more important for rivals’ capital allocation than for near-term share loss. MDT and other aspirants can point to a softer growth print to justify continued R&D spend, but that does not change the switching-cost moat or the installed-base flywheel; the real competitive threat would be evidence that new placements are no longer converting into procedure growth at the same cadence. If that conversion weakens, the valuation premium can compress even while revenue still grows double-digits.

The cleaner risk is China and other procurement-sensitive markets: if healthcare cost scrutiny broadens, system sales can decouple from procedure growth because capital budgets are lumpy. That is a 6-18 month issue, not a one-quarter issue, and it would show up first in system bookings and utilization rather than headline revenue. Falsifier for the bearish case: another quarter of high-teens procedure growth or a re-acceleration in U.S. da Vinci procedures would quickly reopen the stock.